What is ResMed's SG&A?

ResMed (RMD) reported SG&A of $285.66M in Q1 2026.

How has ResMed's SG&A changed year-over-year?

ResMed's SG&A increased by 16.5% year-over-year, from $245.3M to $285.66M.

What is the long-term trend for ResMed's SG&A?

Over 3 years (2022 to 2025), ResMed's SG&A has grown at a 10.3% compound annual growth rate (CAGR), from $737.51M to $991.02M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

ResMed RMD SG&A

Discontinued — last reported Q3 '26

SG&A at other companies

Eli LillyLLY

$2.93B+18.9%

Five Point Holdings, Inc.FPH

$14.75M-0.1%

Inspire Medical SystemsINSP

$152.2M+5.5%

Viemed Healthcare, Inc.VMD

$34.79M+22.4%

LivaNovaLIVN

$143.57M+11.2%

MedtronicMDT

$3.06B+12.4%

Segments

By segment

See full

Sleep And Breathing Health$149.51M+23.0%

Residential Care Software$35.56M+2.4%

Other financials

Income statement

See full

Revenue$1.4B+10.8%

Gross profit$891.0M+16.3%

Operating income$499.8M+17.3%

Net income$398.7M+9.2%

EPS (diluted)$2.74+10.5%

Balance sheet

See full

Cash & equivalents$1.7B+78.0%

Total debt$1.1B+29.8%

Total equity$6.5B+17.1%

Total assets$8.8B+16.1%

Cash flow

See full

Operating cash flow$554.1M-4.2%

CapEx$33.7M+61.8%

Free cash flow$520.5M-6.7%

Valuation

See full

Market cap$29.05B-22.6%

Enterprise value$28.5B-23.3%

P/E19.1×-7.7×

P/S5.3×-2.0×

Profitability

See full

Gross margin61.6%+2.8pp

Operating margin34.2%+2.1pp

Net margin27.4%+1.3pp

FCF margin31.7%+0.4pp

Returns & leverage

See full

Return on equity25.2%-0.6pp

Debt / equity0.2×0.0×

Current ratio3×-0.4×

Where this comes from

Reported directly by ResMed in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: ResMed’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about ResMed's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ResMed's SG&A?: ResMed (RMD) reported SG&A of $285.66M in Q1 2026.
How has ResMed's SG&A changed year-over-year?: ResMed's SG&A increased by 16.5% year-over-year, from $245.3M to $285.66M.
What is the long-term trend for ResMed's SG&A?: Over 3 years (2022 to 2025), ResMed's SG&A has grown at a 10.3% compound annual growth rate (CAGR), from $737.51M to $991.02M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.